This analysis showed that in 9 of 14 individuals, the lowest levels of the GP2-immune-metagene signature were in liver metastases (Fig. 3a,b), and in many of these individuals, this immune signature is lower in the liver metastases than in the matched primary tumor but is often higher in lung metastases (Fig. 3a,b). The gene discussed is GP2; the disease is neoplasm.